FOLH1 and prostate carcinoma: Patient plasmas from healthy volunteers (n = 22, median age = 24 yrs, age range = 21-37 yrs, 13 male/9 female), patients diagnosed with benign prostatic hyperplasia (BPH, n = 156), localized prostate cancer (n = 256), and with castration resistant prostate cancer (n = 67) were analyzed and PSMA+ve submicron events were enumerated in each of these plasma samples (Figure S4).